Valuation: BioNTech SE

Market Cap 20.34B 23.26B 18.76B 17.25B 32.68B 2,238B 33.24B 224B 87.89B 1,094B 87.36B 85.45B 3,771B P/E 2026 *
-18.3x
P/E 2027 * -17.6x
Enterprise Value 9.48B 10.85B 8.75B 8.04B 15.24B 1,044B 15.5B 104B 40.98B 510B 40.74B 39.85B 1,758B EV / Sales 2026 *
4.37x
EV / Sales 2027 * 4.95x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day+0.28%
1 week-0.94%
Current month-1.01%
1 month+2.92%
3 months-9.80%
6 months-15.50%
Current year-3.25%
1 week 88.35
Extreme 88.35
93.44
1 month 88.35
Extreme 88.35
98.81
Current year 79.52
Extreme 79.52
124
1 year 79.52
Extreme 79.52
124
3 years 76.53
Extreme 76.5301
131.49
5 years 76.53
Extreme 76.5301
464
10 years 12.52
Extreme 12.525
464
Manager TitleAgeSince
Chief Executive Officer 60 02/06/2008
Chief Tech/Sci/R&D Officer 59 01/01/2018
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Director/Board Member 72 01/01/2022
Director/Board Member 69 02/06/2008
Director/Board Member 65 15/05/2026
Date Insider Type Main position Quantity % Market Cap.
12/05Free

Chief Operating Officer

22,655 0.0094%
12/05Free

Chief Financial Officer

33,982 0.0141%
12/05Free

Head of Human Resources

18,879 0.0078%
Change 5-day change 1-year change 3-year change Capi.($)
+0.24%-0.94%-18.12%-14.08% 23.26B
+3.13%+13.95%+64.21%+94.35% 57.82B
+0.69%-5.12%+55.56%+72.76% 53.71B
-2.41%-9.53%+2.29%+416.86% 23.8B
-0.56%+10.26%+44.03%-3.86% 20.7B
-0.29%-2.59%+33.67%-30.01% 17.81B
+10.00%-4.30%+208.33%+370.99% 16.9B
-2.61%+8.99%+46.11%+691.67% 16.36B
+0.60%-1.86%+25.06%+192.03% 13.96B
-1.36%-2.61%+58.10%+144.54% 12.69B
Average +0.75%+1.01%+51.92%+193.52% 25.7B
Weighted average by Cap. +1.05%+1.15%+51.37%+157.35%

Financials

2026 *2027 *
Net sales 2.17B 2.48B 2B 1.84B 3.48B 239B 3.54B 23.88B 9.37B 117B 9.31B 9.11B 402B 2.23B 2.55B 2.06B 1.89B 3.58B 246B 3.65B 24.57B 9.64B 120B 9.58B 9.37B 414B
Net income -1.04B -1.19B -961M -884M -1.67B -115B -1.7B -11.48B -4.5B -56.06B -4.48B -4.38B -193B -1.16B -1.33B -1.07B -988M -1.87B -128B -1.9B -12.83B -5.03B -62.65B -5B -4.89B -216B
Net Debt -10.85B -12.41B -10.01B -9.2B -17.44B -1,195B -17.74B -120B -46.9B -584B -46.62B -45.6B -2,012B -9.29B -10.62B -8.57B -7.87B -14.92B -1,022B -15.17B -102B -40.12B -499B -39.88B -39.01B -1,722B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
17/07/26 USD 92.11 +0.13% 140,738
15/07/26 USD 91.99 +1.76% 761,875
14/07/26 USD 90.40 +0.37% 923,470
13/07/26 USD 90.07 -1.55% 671,508
10/07/26 USD 91.49 -1.60% 551,755
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
80.43EUR
Average target price
106.79EUR
Spread / Average Target
+32.78%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BNTX Stock